Provided by Tiger Fintech (Singapore) Pte. Ltd.

Molecular Partners AG

3.76
-0.5200-12.15%
Volume:6.46K
Turnover:25.83K
Market Cap:138.65M
PE:-2.14
High:4.26
Open:4.13
Low:3.76
Close:4.28
Loading ...

Company Profile

Company Name:
Molecular Partners AG
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
159
Office Location:
Wagistrasse 14,Schlieren,Zurich,Switzerland
Zip Code:
8952
Fax:
41 44 755 77 07
Introduction:
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Directors

Name
Position
Patrick Amstutz
Chief Executive Officer and Director
William M. Burns
Chairman of the Board
Agnete Fredriksen
Director
Dominik Hochli
Director
Michael Vasconcelles
Director
Sandip Kapadia
Director
Steven H. Holtzman
Director
Vito Palombella
Director

Shareholders

Name
Position
Patrick Amstutz
Chief Executive Officer and Director
Michael Tobias Stumpp
Chief Operating Officer
Andreas Emmenegger
Chief Financial Officer
Nicolas Leupin
Chief Medical Officer